ARWR · Arrowhead Pharmaceuticals Inc
United States · RS rating 25 · As of 2026-10-14
| Price | 58.37 USD |
|---|---|
| 1-day change | +0.4% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 13 / 21 / 91 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 37 / 27 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -522.7% |
| Sales growth Q/Q | +3.0% |
| Distance from 52-week high | +34.9% |
| Market cap (USD) | $10.4B |